363 related articles for article (PubMed ID: 38481999)
1. Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time.
Zhou M; Bracci PM; McCoy LS; Hsuang G; Wiemels JL; Rice T; Zheng S; Kelsey KT; Wrensch MR; Wiencke JK
Int J Cancer; 2015 Aug; 137(4):826-36. PubMed ID: 25604093
[TBL] [Abstract][Full Text] [Related]
2. Systemic and local immunosuppression in glioblastoma and its prognostic significance.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Pavlov KA; Chekhonin VP
Front Immunol; 2024; 15():1326753. PubMed ID: 38481999
[TBL] [Abstract][Full Text] [Related]
3. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients.
Cheng H; Luo G; Lu Y; Jin K; Guo M; Xu J; Long J; Liu L; Yu X; Liu C
Pancreatology; 2016; 16(6):1080-1084. PubMed ID: 27665172
[TBL] [Abstract][Full Text] [Related]
4. A map of the spatial distribution and tumour-associated macrophage states in glioblastoma and grade 4 IDH-mutant astrocytoma.
Yin W; Ping YF; Li F; Lv SQ; Zhang XN; Li XG; Guo Y; Liu Q; Li TR; Yang LQ; Yang KD; Liu YQ; Luo CH; Luo T; Wang WY; Mao M; Luo M; He ZC; Cao MF; Chen C; Miao JY; Zeng H; Wang C; Zhou L; Yang Y; Yang X; Wang QH; Feng H; Shi Y; Bian XW
J Pathol; 2022 Oct; 258(2):121-135. PubMed ID: 35723032
[TBL] [Abstract][Full Text] [Related]
5. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
[TBL] [Abstract][Full Text] [Related]
7. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
[TBL] [Abstract][Full Text] [Related]
8. Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma.
Weller M; Felsberg J; Hentschel B; Gramatzki D; Kubon N; Wolter M; Reusche M; Roth P; Krex D; Herrlinger U; Westphal M; Tonn JC; Regli L; Maurage CA; von Deimling A; Pietsch T; Le Rhun E; Reifenberger G
Acta Neuropathol; 2024 Jan; 147(1):11. PubMed ID: 38183430
[TBL] [Abstract][Full Text] [Related]
9. Druggable genomic landscapes of high-grade gliomas.
Ghanem P; Fatteh M; Kamson DO; Balan A; Chang M; Tao J; Blakeley J; ; Canzoniero J; Grossman SA; Marrone K; Schreck KC; Anagnostou V
Front Med (Lausanne); 2023; 10():1254955. PubMed ID: 38143440
[TBL] [Abstract][Full Text] [Related]
10. Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China.
Wang Y; Lu J; Wu C; Fei F; Chu Z; Lu P
Front Immunol; 2023; 14():1276107. PubMed ID: 38124739
[TBL] [Abstract][Full Text] [Related]
11. Multiomic spatial landscape of innate immune cells at human central nervous system borders.
Sankowski R; Süß P; Benkendorff A; Böttcher C; Fernandez-Zapata C; Chhatbar C; Cahueau J; Monaco G; Gasull AD; Khavaran A; Grauvogel J; Scheiwe C; Shah MJ; Heiland DH; Schnell O; Markfeld-Erol F; Kunze M; Zeiser R; Priller J; Prinz M
Nat Med; 2024 Jan; 30(1):186-198. PubMed ID: 38123840
[TBL] [Abstract][Full Text] [Related]
12. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.
Malta TM; Sabedot TS; Morosini NS; Datta I; Garofano L; Vallentgoed W; Varn FS; Aldape K; D'Angelo F; Bakas S; Barnholtz-Sloan JS; Gan HK; Hasanain M; Hau AC; Johnson KC; Cazacu S; deCarvalho AC; Khasraw M; Kocakavuk E; Kouwenhoven MCM; Migliozzi S; Niclou SP; Niers JM; Ormond DR; Paek SH; Reifenberger G; Sillevis Smitt PA; Smits M; Stead LF; van den Bent MJ; Van Meir EG; Walenkamp A; Weiss T; Weller M; Westerman BA; Ylstra B; Wesseling P; Lasorella A; French PJ; Poisson LM; ; Verhaak RGW; Iavarone A; Noushmehr H
Cancer Res; 2024 Mar; 84(5):741-756. PubMed ID: 38117484
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]